As per the latest research report, the size of the market of insulin delivery devices in the Middle East & Africa is estimated to be worth USD 910 million by 2027 from USD 700 million in 2022, projecting a CAGR of 5.29% from 2022 to 2027.
Insulin maintains sugar levels in the blood and is essential for people who have type I diabetes & type II diabetes in the Middle East and Africa. Therefore, the development of insulin delivery devices has been encouraged recently. These devices deliver insulin doses via the parenteral route rather than the oral route of administration. Insulin delivery devices promote the absorption rate of insulin into the bloodstream from injection to execute immediate pharmacological action of insulin. Some majorly used insulin delivery devices include insulin syringes, insulin pens, insulin pen needles, insulin pumps, and insulin jet injectors.
The growing aging population, increasing the incidence rate of diabetes among the population, rising government initiatives towards diabetes, and growing awareness among diabetes patients are factors driving the growth of the insulin delivery devices market in the Middle East and Africa. Nearly 73 million people aged between 20 to 75 had diabetes in the Middle East and Africa in 2021. Most people have type 2 diabetes in this region. People with diabetes use insulin intake by syringes and other methods to level the glucose in the blood. Type 1 diabetes patients require lifelong insulin to maintain the glucose level in the blood to stay in a safe zone. For these types of people, an automated insulin delivery system has developed. Insulin delivery devices send insulin every 5 minutes or at the time mentioned. High-diabetes patients use these devices to improve their wellness of the life.
YOY growth in obesity cases and people with unhealthy lifestyles are anticipated to promote the insulin delivery devices market in the Middle East and Africa. Increasing unhealthy food such as junk food, soft drinks which contain high sugar levels, and lack of exercise are the primary factor for the increased glucose level in the body. This fluctuation in glucose level may occur at any age, and these people are required to have insulin intake to reduce the sudden collapse and risk in their life.
Technological developments and growing efforts from manufacturers to develop advanced and cost-effective insulin delivery devices are anticipated to showcase a positive influence on market growth in the Middle East and Africa. Owing to the increased adoption of the latest technology in manufacturing insulin devices that can reduce pain and increase the quality of life. Some advanced devices are insulin pens, jet injectors, insulin pumps, and artificial pancreas with a closed-loop delivery system. In addition, some of the insulin pumps use a remote-control system for an insulin pump for young patients who are suffering from diabetes.
However, insufficient healthcare infrastructure to maintain the advanced insulin delivery devices, inadequate number of physicians, and unavailability of social and economic facilities are expected to restrain the market growth in the Middle East and Africa. In addition, the availability of oral drugs for insulin, high costs associated with insulin delivery devices, lack of awareness of the advanced insulin devices, and lack of product approvals are restraining the market growth.
This research report on the MEA Insulin Delivery Devices Market has been segmented and sub-segmented into the following categories:
The MEA Insulin Delivery Devices market is expected to record a considerable share in the global market during the forecast period. Over recent years, the prevalence of diabetes in people in the Middle East and Africa has increased dramatically. It is the rise in the prevalence of cardiovascular diseases and obesity that is driving the market growth. However, the growing diabetes population is driving the demand for insulin delivery devices. Presently diabetes has affected over 5.42 million individuals in Saudi Arabia.
South Africa held the largest share of the insulin delivery devices market in the Middle East and Africa in 2021. This is because the presence of the diabetic population significantly contributes to the insulin market growth. The prevalence of diabetes in South Africa is over 9%, with rising the other problems, obesity, and healthcare expenditure. Moreover, the growing diabetes population drives the demand for insulin delivery devices.
Furthermore, the counties such as UAE and Saudi Arabia are projected to witness a considerable share and contribute to the MEA regional market growth. The market growth is attributed to the growing need for insulin has prompted extensive R&D efforts to develop painless insulin delivery systems, such as CGM-integrated insulin pumps. Earlier syringes were the only way to administer insulin initially, and they were unpleasant and inconvenient to use. Therefore, this features a fixed dosage form and is less uncomfortable to use; it will also help minimize insulin waste.
KEY MARKET PLAYERS:
Companies like Becton, Dickinson, and Company (U.S.), Sanofi (France), Novo Nordisk A/S (Denmark), Julphar (U.A.E.), Eli Lilly and Company (U.S.), Biocon Ltd. (India), Ypsomed AG (Switzerland), Wockhardt Ltd. (India), B. Braun Meselgen AG (Switzerland) and Biodel Inc. (U.S.) are playing a promising role in the MEA Insulin Delivery Devices Market.
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: firstname.lastname@example.org